Cargando…

Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab

Detalles Bibliográficos
Autores principales:	Na, Zhenkun, Yeo, Siok Ping, Bharath, Sakshibeedu R, Bowler, Matthew W, Balıkçı, Esra, Wang, Cheng-I, Song, Haiwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223238/ https://www.ncbi.nlm.nih.gov/pubmed/27325296 http://dx.doi.org/10.1038/cr.2016.77

Ejemplares similares

Structural basis for specific recognition of pre-snRNA by Gemin5
por: Tang, Xuhua, et al.
Publicado: (2016)

Structural basis for reactivating the mutant TERT promoter by cooperative binding of p52 and ETS1
por: Xu, Xueyong, et al.
Publicado: (2018)

Structural basis for DNA unwinding at forked dsDNA by two coordinating Pif1 helicases
por: Su, Nannan, et al.
Publicado: (2019)

High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1
por: Horita, Shoichiro, et al.
Publicado: (2016)

Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry
por: Tavares, Ana Beatriz M. L. A., et al.
Publicado: (2018)

Structural insights into the substrate-bound condensation domains of non-ribosomal peptide synthetase AmbB
por: Chu Yuan Kee, Melissa-Jane, et al.
Publicado: (2022)

Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab
por: Zhang, Fei, et al.
Publicado: (2017)

Crystal structure of the INTS3/INTS6 complex reveals the functional importance of INTS3 dimerization in DSB repair
por: Jia, Yu, et al.
Publicado: (2021)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Blocking the PD-1/PD-L1 axis in dendritic cell-stimulated Cytokine-Induced Killer Cells with pembrolizumab enhances their therapeutic effects against hepatocellular carcinoma
por: Zhang, Wan, et al.
Publicado: (2019)

Structural basis of suppression of host translation termination by Moloney Murine Leukemia Virus
por: Tang, Xuhua, et al.
Publicado: (2016)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
por: O’Neil, Bert H., et al.
Publicado: (2017)

Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model
por: Lee, Eun-Ji, et al.
Publicado: (2021)

The Three P's: Parotid, PD-L1, and Pembrolizumab
por: Wiggins, Amanda, et al.
Publicado: (2019)

Investigation of Molecular Interactions Mechanism of Pembrolizumab and PD-1
por: Wang, Simiao, et al.
Publicado: (2023)

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
por: Ott, P. A., et al.
Publicado: (2017)

The Ighmbp2 helicase structure reveals the molecular basis for disease-causing mutations in DMSA1
por: Lim, Siew Choo, et al.
Publicado: (2012)

Developing a highly efficient hydroxytyrosol whole-cell catalyst by de-bottlenecking rate-limiting steps
por: Yao, Jun, et al.
Publicado: (2020)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
por: Mehnert, Janice M., et al.
Publicado: (2019)

PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy
por: Möhn, Nora, et al.
Publicado: (2021)

High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
por: Ahn, Soomin, et al.
Publicado: (2020)

Model‐Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti–PD‐1 Monoclonal Antibody in Advanced Solid Tumors
por: Ahamadi, M, et al.
Publicado: (2016)

Antibody Structure and Function: The Basis for Engineering Therapeutics
por: Chiu, Mark L., et al.
Publicado: (2019)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

Pembrolizumab Induces an Unexpected Conformational Change in the CC′-loop of PD-1
por: Roither, Bernhard, et al.
Publicado: (2020)

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
por: Shimizu, Toshio, et al.
Publicado: (2016)

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose‐Range Selection of the Anti–PD‐1 Antibody Pembrolizumab
por: Lindauer, A, et al.
Publicado: (2016)

SAT-584 Pembrolizumab-Related Graves' Disease: A Rare Adverse Effect of an Anti-PD-1 Antibody Cancer Immunotherapy
por: Narayen, Garima, et al.
Publicado: (2019)

Author Correction: High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
por: Ahn, Soomin, et al.
Publicado: (2020)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Pembrolizumab-Induced Mobitz Type 2 Second-Degree Atrioventricular Block
por: Khan, Alisha, et al.
Publicado: (2020)

Structural and Mutational Studies on Substrate Specificity and Catalysis of Salmonella typhimurium D-Cysteine Desulfhydrase
por: Bharath, Sakshibeedu R., et al.
Publicado: (2012)

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
por: Zhou, Yixin, et al.
Publicado: (2019)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
por: Liu, Qiao, et al.
Publicado: (2022)

The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
por: Brar, Gagandeep, et al.
Publicado: (2019)

(89)Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs
por: van der Veen, Elly L, et al.
Publicado: (2020)

Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
por: Eun, Yeonghee, et al.
Publicado: (2019)

SAT-242 Isolated Adrenocorticotropic Hormone Deficiency Secondary to the PD-1 Inhibitor Pembrolizumab
por: Mathew, Justin, et al.
Publicado: (2020)

Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
por: Gorshein, Elan, et al.
Publicado: (2021)

Radiation therapy enhanced therapeutic efficacy of anti-PD1 against gastric cancer
por: Hong, Sen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g91ggv9c008ugatp62uugr0voo